Indeed, in April [2024], the Yale School of Medicine published the results of the first randomised control study of psilocybin for pain relief. Although it enrolled just 10 CH [Cluster Headache] sufferers, half of those who received psilocybin as opposed to a placebo reported a reduction in attacks. Precisely how psilocybin interrupts the cycle of headaches is an open question. Brain scans suggest…
The FDA is permitting a large cohort of American veterans to smoke medical cannabis in a study aimed at gaining insights for combatting PTSD. The Multidisciplinary Association for Psychedelic Studies (MAPS) has been pushing for this since 2021. The Multidisciplinary Association for Psychedelic Studies, or MAPS, announced… that the U.S. Food and Drug Administration (FDA)…
The research… from Johns Hopkins University, surveyed 879 healthcare providers, shedding light on current attitudes, knowledge levels, and concerns… The vast majority of respondents, 93%, endorsed the potential of psilocybin and 76% supported the promise of MDMA in clinical settings. However, self-reported knowledge did not align with objective assessments. While participants rated their understanding of psilocybin’s…
Lauren Dayton said she has suffered from cluster headaches, also known as suicide headaches, for more than a decade, and this is the only treatment that’s worked. “I have had no hope with this painful disease – none – until citizen science led me this way,” Lauren said. New Jersey Senate Budget Committee approved the…
A direct comparison between the experimental psychedelic drug psilocybin and a standard SSRI antidepressant shows similar improvement of depressive symptoms, but that psilocybin offers additional longer-term benefits… Lead researcher Mr. Tommaso Barba (Ph.D. candidate from Imperial College, London) said, “This is the first work to compare the long-term effects of these two drugs in the…
By August 11 [2024], the Food and Drug Administration is expected to decide whether MDMA – the chemical found in ecstasy or molly – can be prescribed as a treatment for post-traumatic stress disorder. The downvote in June [2024] – not to mention controversy about the trials that spilled into full view during a public hearing –…
A 51-year-old Calgary man who suffers debilitating cluster headaches has won a Federal Court battle forcing Health Canada to reconsider his bid for legal access to psilocybin to treat his extreme pain. …the decision to deny Lance access to the drug “unreasonable” and “unintelligible.” Health Canada told Canadian Broadcasting Center News via email that it…
Here’s another… under-studied prospect of psychedelics: a world without severe chronic pain. And… around the internet or psychedelic conferences, a whole subterranean trove of similar stories opens up. An estimated 51 million Americans suffer from chronic pain – excruciating conditions like migraines, phantom limb pains, or fibromyalgia – and often go without effective treatments. But psychedelics like psilocybin mushrooms and LSD seem to…
…this will… be the first time in 25 years that the FDA will review a new treatment for PTSD… The FDA is set to decide on the therapy’s fate by the middle of August [2024]… if rescheduled, then lobbying efforts will shift to individual states. Some have policies on the books that will immediately follow…
That question is now before one of the nation’s highest courts… …pitting the DEA’s law enforcement authority against state powers to regulate medicine… Washington, Washington D.C., Delaware, Illinois, Michigan, Minnesota, Nevada, Oregon and Pennsylvania… have weighed in directly… the state coalition filed a brief that accused the DEA of reaching far beyond its law enforcement…
Recent Comments